656 related articles for article (PubMed ID: 18690004)
21. [Possibilities for modifying risk factors for chromosome abnormalities--advantages of the so-called "triple" marker studies in comparison with pure "maternal age screening"].
Holzgreve W; Schloo R; Veress L; Schlegel W; Tercanli S; Schneider HP
Zentralbl Gynakol; 1994; 116(11):643-8. PubMed ID: 7871918
[TBL] [Abstract][Full Text] [Related]
22. Prenatal genetic screening for Down syndrome and open neural tube defects using maternal serum markers in Thai pregnant women.
Wasant P; Liammongkolkul S
Southeast Asian J Trop Med Public Health; 2003; 34 Suppl 3():244-8. PubMed ID: 15906746
[TBL] [Abstract][Full Text] [Related]
23. [How to improve the screening and diagnosis of fetal aneuploidy?].
Ville Y
Bull Acad Natl Med; 2005 Nov; 189(8):1773-84; discussion 1784-7. PubMed ID: 16737102
[TBL] [Abstract][Full Text] [Related]
24. Maternal serum alpha-fetoprotein screening: benefits, risks, and costs.
Campbell TL
J Fam Pract; 1987 Nov; 25(5):461-7. PubMed ID: 2445897
[TBL] [Abstract][Full Text] [Related]
25. [Serum screening in pregnant women for Down syndrome and open neural tube defects; testing of Health Council's criteria for genetic screening].
Kleiverda G
Ned Tijdschr Geneeskd; 1996 Mar; 140(9):507. PubMed ID: 8628441
[No Abstract] [Full Text] [Related]
26. Cost-effectiveness analysis of prenatal diagnosis intervention for Down's syndrome in China.
Chen Y; Qian X; Li J; Zhang J; Chu A; Schweitzer SO
Int J Technol Assess Health Care; 2007; 23(1):138-45. PubMed ID: 17234028
[TBL] [Abstract][Full Text] [Related]
27. The impact of first-trimester screening on AMA patients' uptake of invasive testing.
Wray AM; Ghidini A; Alvis C; Hodor J; Landy HJ; Poggi SH
Prenat Diagn; 2005 May; 25(5):350-3. PubMed ID: 15906421
[TBL] [Abstract][Full Text] [Related]
28. A cost-benefit analysis of prenatal diagnosis for neural tube defects selectively offered to relatives of index cases.
Sadovnick AD; Baird PA
Am J Med Genet; 1982 May; 12(1):63-73. PubMed ID: 6807091
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Nicolaides' risk evaluation for Down's syndrome with a novel software: an analysis of 1,463 cases.
Schmidt P; Staboulidou I; Soergel P; Wüstemann M; Hillemanns P; Scharf A
Arch Gynecol Obstet; 2007 Jun; 275(6):469-74. PubMed ID: 17333228
[TBL] [Abstract][Full Text] [Related]
30. Nuchal translucency screening: how do women actually utilize the results?
Caughey AB; Musci TJ; Belluomini J; Main D; Otto C; Goldberg J
Prenat Diagn; 2007 Feb; 27(2):119-23. PubMed ID: 17152116
[TBL] [Abstract][Full Text] [Related]
31. [Serum screening of fetal chromosome abnormality during second pregnancy trimester: results of 26,803 pregnant women in Jiangsu Province].
Hu YL;
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(35):2476-80. PubMed ID: 18067809
[TBL] [Abstract][Full Text] [Related]
32. Maternal serum screening.
Lofsky S
CMAJ; 1999 Apr; 160(8):1125-6. PubMed ID: 10234332
[No Abstract] [Full Text] [Related]
33. Incorporating first-trimester Down syndrome studies into prenatal screening: executive summary of the National Institute of Child Health and Human Development workshop.
Reddy UM; Mennuti MT
Obstet Gynecol; 2006 Jan; 107(1):167-73. PubMed ID: 16394055
[TBL] [Abstract][Full Text] [Related]
34. Trends in prenatal screening and diagnostic testing among women referred for advanced maternal age.
Nakata N; Wang Y; Bhatt S
Prenat Diagn; 2010 Mar; 30(3):198-206. PubMed ID: 20063323
[TBL] [Abstract][Full Text] [Related]
35. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.
Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN
Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658
[TBL] [Abstract][Full Text] [Related]
36. Fetal chromosomal abnormalities: antenatal screening and diagnosis.
Anderson CL; Brown CE
Am Fam Physician; 2009 Jan; 79(2):117-23. PubMed ID: 19178062
[TBL] [Abstract][Full Text] [Related]
37. Maternal serum screening for neural tube defects and Down's syndrome.
Robertson EF
Med J Aust; 1991 Jul; 155(2):67-8. PubMed ID: 1713290
[No Abstract] [Full Text] [Related]
38. Cost-effectiveness analysis of triple test in second-trimester maternal serum screening for Down's syndrome: an experience from Taiwan with decreasing birth rate but increasing population of old pregnant women.
Hwa HL; Yen MF; Lin CL; Ko TM; Hsieh FJ; Chen TH
J Eval Clin Pract; 2008 Apr; 14(2):191-7. PubMed ID: 18284525
[TBL] [Abstract][Full Text] [Related]
39. Fetal Down syndrome screening: a cost effectiveness analysis of alternative screening programs.
Cusick W; Vintzileos AM
J Matern Fetal Med; 1999; 8(6):243-8. PubMed ID: 10582856
[TBL] [Abstract][Full Text] [Related]
40. Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening?
Comstock CH; Malone FD; Ball RH; Nyberg DA; Saade GR; Berkowitz RL; Ferreira J; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Bianchi DW; D'Alton ME;
Am J Obstet Gynecol; 2006 Sep; 195(3):843-7. PubMed ID: 16949423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
